78 related articles for article (PubMed ID: 2654403)
21. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Nannan Panday VR; de Wit R; Schornagel JH; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 1999; 44(4):349-53. PubMed ID: 10447584
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of cisplatin in combination with glutathione.
Plaxe S; Freddo J; Kim S; Kirmani S; McClay E; Christen R; Braly P; Howell S
Gynecol Oncol; 1994 Oct; 55(1):82-6. PubMed ID: 7959273
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy of solid tumors in private practice in Malaysia.
Narasimha K
Gan To Kagaku Ryoho; 1992 Jul; 19(8 Suppl):1220-3. PubMed ID: 1514835
[No Abstract] [Full Text] [Related]
25. [Verify the optimum administration of anticancer agent--cisplatin].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1339-44. PubMed ID: 11681239
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
Johnson CA; Kilpatrick D; von Roemeling R; Langer C; Graham MA; Greenslade D; Kennedy G; Keenan E; O'Dwyer PJ
J Clin Oncol; 1997 Feb; 15(2):773-80. PubMed ID: 9053504
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer.
van der Gaast A; Kok TC; Kerkhofs L; Siersema PD; Tilanus HW; Splinter TA
Br J Cancer; 1999 Jun; 80(7):1052-7. PubMed ID: 10362115
[TBL] [Abstract][Full Text] [Related]
28. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Hainsworth JD; Hesketh PJ
Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
[TBL] [Abstract][Full Text] [Related]
29. [Antiemetic therapy in cisplatin chemotherapy].
Grünsteidel W; Schmidt C; Tulusan AH; Merkle E
Gynakol Rundsch; 1989; 29 Suppl 2():374-7. PubMed ID: 2613053
[No Abstract] [Full Text] [Related]
30. Persistent nephrotoxicity during 10-year follow-up after cisplatin or carboplatin treatment in childhood: relevance of age and dose as risk factors.
Skinner R; Parry A; Price L; Cole M; Craft AW; Pearson AD
Eur J Cancer; 2009 Dec; 45(18):3213-9. PubMed ID: 19850470
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
[TBL] [Abstract][Full Text] [Related]
32. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
[TBL] [Abstract][Full Text] [Related]
33. Several apparent errors surfaced on reading the article in the June 2002 issue of Alternative Medicine Review by Kodama et al. entitled "Can maitake MD-fraction aid cancer patients"?
Black W
Altern Med Rev; 2002 Dec; 7(6):451; author reply 452-4. PubMed ID: 12495370
[No Abstract] [Full Text] [Related]
34. A novel combination of cisplatin, irinotecan, and capecitabine in patients with advanced cancer.
Jefford M; Michael M; Rosenthal MA; Davis ID; Green M; McClure B; Smith J; Waite B; Zalcberg J
Invest New Drugs; 2004 Apr; 22(2):185-92. PubMed ID: 14739668
[TBL] [Abstract][Full Text] [Related]
35. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Ren Y; Li Y; Liu J
Int J Gynecol Cancer; 2011 May; 21(4):685-9. PubMed ID: 21543932
[TBL] [Abstract][Full Text] [Related]
36. Phase I study of high-dose cytarabine and cisplatin in patients with advanced malignancy.
Atkins JN; Muss HB; Capizzi RL; Cooper MR; Craig J; Cruz JM; Jackson DV; Powell B; Richards F; Spurr CL
Cancer Treat Rep; 1985; 69(7-8):897-9. PubMed ID: 4040427
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and efficacy of weekly intraarterial cisplatin in locally advanced (stage III and IV) head and neck cancers.
Mortimer JE; Taylor ME; Schulman S; Cummings C; Weymuller E; Laramore G
J Clin Oncol; 1988 Jun; 6(6):969-75. PubMed ID: 3373266
[TBL] [Abstract][Full Text] [Related]
38. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.
Bahleda R; Baker J; Massard C; Gadgeel SM; Rogers JE; Izzedine H; Deutsch E; Garris JL; Khan A; Boelle E; Assadourian S; Soria JC; Ajani JA
Oncology; 2016; 90(1):10-20. PubMed ID: 26492090
[TBL] [Abstract][Full Text] [Related]
39. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer.
Shen YC; Li CP; Yen CJ; Hsu C; Lin YL; Lin ZZ; Chen LT; Su WC; Chao Y; Yeh KH; Cheng AL
Oncology; 2014; 87(2):104-13. PubMed ID: 25011938
[TBL] [Abstract][Full Text] [Related]
40. Effect of treatment schedule on the interaction of Cisplatin and radiation in human lung cancer cells.
Asaka-Amano Y; Takiguchi Y; Yatomi M; Kurosu K; Kasahara Y; Tanabe N; Tatsumi K; Kuriyama T
Radiat Res; 2007 Jun; 167(6):637-44. PubMed ID: 17523845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
